Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Financial Results:
Glenmark Pharmaceuticals Ltd reported Revenues for Q3FY25 of ₹1,926.00 Crores up from ₹2,507.00 Crore year on year, a rise of 5.77%.
Total Expenses for Q3FY25 of ₹1,736.00 Crores up from ₹1,590.00 Crores year on year, a rise of 9.18%.
Consolidated Net Profit of ₹128.00 Crores down 16.34% from ₹153.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹11.02, Sales 17.02% from ₹13.28 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
